Key Takeaways
- Liraglutide is a once-daily GLP-1 injection — the main practical difference from once-weekly semaglutide and tirzepatide.
- Its most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — and improve as the dose is raised gradually.
- Serious but uncommon risks include pancreatitis, gallbladder disease, allergic reactions, kidney injury from dehydration, a small rise in heart rate, and a boxed warning about thyroid C-cell tumors (seen in rodents).
- Severe gastrointestinal reactions were reported somewhat more often on liraglutide than placebo in trials (about 4.8% vs 1.4%).
- This is general education. Report anything severe or persistent, and never change your dose on your own.
What liraglutide is
Liraglutide is a GLP-1 receptor agonist sold as Saxenda (chronic weight management) and Victoza (type 2 diabetes). Unlike the once-weekly options, it is a once-daily injection. It is an older, well-characterized drug in this class, and its side effects are mostly digestive for the same reason as the others — it slows stomach emptying and reduces appetite. See our full liraglutide profile for the overview.
Common side effects
From the Saxenda prescribing information, the most common effects are:
- Nausea — the most common, especially when starting and during dose increases.
- Diarrhea and constipation.
- Vomiting.
- Decreased appetite, indigestion, and abdominal pain.
- Low blood sugar (hypoglycemia) — mainly in people with type 2 diabetes, particularly if also on insulin or a sulfonylurea.
- Fatigue, dizziness, and headache.
- Injection-site reactions — more relevant here than for weekly drugs, since you inject daily.
In the Saxenda trials, severe gastrointestinal reactions were more frequent on liraglutide (about 4.8%) than placebo (about 1.4%) — a reminder that while most side effects are mild, they are not trivial for everyone. Gradual dose escalation over several weeks is used specifically to limit them.
Serious side effects to know
Uncommon, but recognize the signs:
- Pancreatitis. Severe, persistent abdominal pain, often radiating to the back — seek urgent care.
- Gallbladder disease. Rapid weight loss raises gallstone risk; upper-right abdominal pain, fever, or jaundice needs evaluation.
- Increased heart rate. Liraglutide can modestly raise resting heart rate; the label advises monitoring heart rate, and you should report a persistently racing or pounding heartbeat.
- Acute kidney injury from dehydration, usually from ongoing vomiting or diarrhea.
- Serious allergic reactions, including anaphylaxis and angioedema (swelling), have been reported — swelling of the face, lips, tongue, or throat, or trouble breathing, is an emergency.
- Thyroid C-cell tumors (boxed warning). Seen in rodents; human risk not established. Contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
How to manage the common ones
The management playbook mirrors the other GLP-1 drugs, with daily dosing in mind:
- Smaller, lower-fat meals, eaten slowly, stopping at the first sign of fullness.
- Stay hydrated, especially through any diarrhea or vomiting.
- Rotate injection sites to reduce local irritation — more important on a daily injection.
- Protect protein and total calories so appetite loss doesn’t become under-eating and muscle loss — see Protein First.
- Raise the dose on schedule, not faster. If a step is hard, ask your prescriber about slowing it.
When to contact your clinician
Seek prompt care for severe abdominal pain, signs of a gallbladder or pancreas problem, an allergic reaction, a persistently elevated heart rate, or dehydration. If side effects are hard to live with, dosing and pace can be adjusted — and it is worth discussing whether a once-weekly option like semaglutide or tirzepatide might suit you better.
General information only — not a substitute for the prescribing information or your clinician’s guidance. See our editorial policy.